Post Doctoral Clinical Training Fellow - Target Validation & DNA Damage Repair Laboratory

01/03/2020, 23:55

Breast Cancer Research
Target Validation and DNA Damage Response
Full time
Fixed Term
2 - 3 years duration to fit around clinical requirements
£40,141 - £55,317 p.a plus £2,162 London weighting
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top five cancer centres globally.

The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

A Postdoctoral Clinical Training Fellow position is available in the joint Tutt/Lord Breast Cancer Now laboratory programme. This position will adopt a “reverse translation” approach, generating and using molecular profiling data (genomics, transcriptomics etc.) from samples from a series of clinical trial collaborations together with functional genomics and wet laboratory validation approaches in model systems to understand outlier responses and mechanisms of resistance to platinum salts and PARP inhibitors used in the treatment of homologous recombination (HR) deficient forms of breast cancer. You will be responsible for the design and the implementation of this project and will work closely with non-clinical Postdoctoral Fellows, Technicians, Bioinformaticians and Staff Scientists to use the information you gain to either identify refined biomarkers of response, new targets in the disease and/or new proof of concept clinical trials aimed at improving outcomes for people diagnosed with breast cancer.

You must possess a PhD in biology, genetics, genomics, molecular pathology or other associated subjects and have a strong track record in biomedical research as demonstrated by high-impact, first author publications. In addition, you must be a senior trainee or be eligible to be on the GMC specialist register in medical or clinical oncology and have eligibility to practice oncology in the UK, allowing maintenance of clinical skills up to 20% FTE. Considerable experience in cancer genomics, molecular pathology, cell and molecular biology is essential. An understanding of DNA Damage Repair biology is a significant advantage. Attention to detail, self-motivation and a collegiate approach to research are essential. This post will give the successful applicant an excellent opportunity to further develop skills as a post-doctoral scientist to enable applications for independent clinician scientist fellowship funding.

The appointment will be on a Fixed Term Contract with flexibility for the role to be between two to three years duration to fit around clinical requirements, with a starting salary in the range of £40,141 - £55,317 p.a. plus £2,162 London weighting, based on experience.

Informal enquiries can be made via email to Professor Andrew Tutt ( and Professor Christopher Lord ( Please note – this address is for enquiries only and you should not send your application to this email address.

We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.

Funded by

Breast Cancer Now
Additional Documentation for Candidates